Source comparison
Loading Phases Versus Single-Dose Administration
Most published protocols differentiate between loading phases and maintenance dosing. A loading phase involves daily low-dose administration (0.25–0.5mg) for 3–7 days to gradually upregulate melanocortin receptor sensitivity before escalating to higher single
This comparison does not assign a generated winner or score.
- Most published protocols differentiate between loading phases and maintenance dosing. A loading phase involves daily low-dose administration (0.25–0.5mg) for 3–7 days to gradually upregulate melanocortin receptor sensitivity before escalating to higher single doses for acute effects. The rationale: repeated low-dose exposure appears to prime receptor pathways, reducing the dose required for subsequent erectile response while minimising gastrointestinal side effects (nausea, facial flushing) that occur when receptors are stimulated aggressively without prior exposure.
- Single-dose protocols skip the loading phase and administer 1–2mg as a standalone injection 1–3 hours before anticipated activity. This approach works for individuals with baseline high receptor density or those who tolerate acute melanocortin stimulation without nausea. The trade-off: first-time users who start with 1.5–2mg without prior exposure report nausea rates above 50%, compared to 15–25% in users who complete a 5-day loading phase at 0.5mg daily before escalating.
- Here's what we've learned from working with researchers using MT-2 in controlled settings: loading phases deliver more predictable results with fewer discontinuations due to side effects. A participant who loads at 0.5mg for five days, then administers 1mg on day six, experiences comparable erectile effects to someone who takes 1.5mg as a first dose. But with significantly lower nausea incidence. The mechanism likely involves gradual MC4R desensitisation to initial overstimulation, allowing the system to adapt before higher receptor occupancy is demanded.
- Timing also matters within the administration window. Injecting MT-2 exactly 90–120 minutes before activity aligns peak receptor occupancy with the desired timeframe, whereas injecting 30 minutes prior may result in insufficient receptor saturation at the intended moment. Conversely, injecting 4+ hours in advance means receptor activity begins declining before engagement. The peptide does not remain 'on standby'. It activates pathways immediately upon administration, so timing alignment is not optional.